Drugs / NTB003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07182552 | Jun 2025 → Feb 2026 overdue | — | Nanjing Chia-tai Tianqing Pharmaceutical | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07462130 | Mar 2026 → May 2027 expected | endocrine exophthalmos | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTB003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07462130 ↗ |
| Route | Subcutaneous | “NTB003 dose 1 administered SC injection every 4 weeks.” NCT07462130 ↗ |